Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)

VernacularTitle:双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识（2024年版）
Keywords: Leukemia, lymphoblastic, acute; Bispecific T cell engager; Immunotherapies
From: Chinese Journal of Hematology 2024;45(7):629-636
CountryChina
Language:Chinese
Abstract: Acute lymphoblastic leukemia (ALL) is one of the most common acute leukemias, with rapid onset and progression. The standardized application of chemotherapy and transplantation have improved the prognosis of patients, while the unmet therapeutic needs still exist. Recently novel immunotherapies including Bispecific T cell Engager develop rapidly, offering more options for ALL treatment and also demanding higher requirements for clinical diagnosis and treatment management. Based on the evidence of domestic and international medical evidence and clinical experience, the expert panel updated Chinese consensus for the Bispeific T cell Engager in the treatment of B-cell acute lymphoblastic leukemia (2022) and formulated this edition of the Chinese expert consensus.